Sanofi scores with its subcutaneous version of Sarclisa as it tries to play catch up with J&J's Darzalex

[cafead]

via Trailing Johnson & Johnson’s powerhouse Darzalex by roughly five years in its development timeline has made it challenging for Sanofi’s Sarclisa—the only other CD38 antibody on the market for multiple myeloma—to compete in the indication.

article source